Why Asthma Research Is Expanding Right Now
The asthma treatment landscape is shifting. In recent months, the FDA approved Breztri as the first triple-combination maintenance therapy for patients aged 12 and older, based on the Phase III KALOS and LOGOS trials. Another medication, EXDENSUR (depemokimab), received approval in late 2025 for severe asthma with an eosinophilic phenotype—given as an injection once every six months. These developments did not happen in a vacuum. They emerged from thousands of volunteer participants who enrolled in asthma clinical trials across the country.
Pharmaceutical companies and academic medical centers are actively recruiting for studies at various phases. Eli Lilly's RENEW-Asthma trial, evaluating brenipatide for moderate-to-severe asthma, spans 121 locations from Tempe, Arizona to Tampa, Florida. The Seabreeze STAT Asthma study, testing rademikibart for acute exacerbations, operates at six U.S. sites. These are not obscure experiments tucked away in university basements—they are mainstream investigations happening in community clinics and major hospitals alike.
The surge in asthma research reflects a broader recognition that the condition is not monolithic. Patients with eosinophilic asthma respond differently than those with allergic asthma, and trials increasingly target specific phenotypes. This precision means asthma research studies are looking for diverse participants: adults, adolescents, people with mild symptoms, and those with severe uncontrolled disease.
What Happens When You Join a Trial
The process is more structured than many newcomers expect. Linda, a 58-year-old retired teacher in Ohio, enrolled in a Phase 2 study after her daughter spotted a listing on ClinicalTrials.gov. She described the screening visit as "a deep dive into my lungs"—spirometry tests, blood draws, allergy panels, and a detailed medical history review. She was assigned a study coordinator who walked her through every form and answered questions about the informed consent document.
Most trials follow a pattern: screening, baseline assessment, treatment period, and follow-up. The treatment period can range from a few weeks to over a year. The RENEW-Asthma trial, for instance, involves approximately 65 weeks of participation, including screening and follow-up. Some studies require overnight stays; others involve brief outpatient visits every few months.
Participants are typically randomized into groups. Some receive the investigational treatment, others a placebo, and sometimes a third group gets a standard therapy for comparison. The key detail many patients miss: even those assigned to the placebo group continue their regular asthma medications. Trials rarely withdraw existing treatment, which means the baseline standard of care remains in place regardless of assignment.
The monitoring is intensive. In Linda's experience, "I saw the research team more often in six months than I had seen my regular doctor in two years." Lung function tests, symptom diaries, and phone check-ins create a safety net that catches subtle changes early. For patients who have felt underserved by the healthcare system, this level of attention can be a meaningful benefit of participating in an asthma clinical trial.
Compensation and Costs: What the Numbers Look Like
Money is often the elephant in the room. Patients wonder whether they will be paid, and if so, how much. The answer varies widely by study length, intensity, and sponsor.
| Study Type | Typical Duration | Compensation Range | Key Benefit | Key Drawback |
|---|
| Short-term observational | 1-4 visits | $100 – $350 | Low time commitment | No access to experimental treatment |
| Phase 2 interventional | 12-24 weeks | $500 – $1,500 | Early access to novel therapy | More frequent visits required |
| Phase 3 interventional | 6-12 months | $1,000 – $3,000+ | Comprehensive health monitoring | Placebo possibility |
| Phase 4 / post-market | 12-52 weeks | $500 – $2,000 | Approved medication under study | Less novel than earlier phases |
| Long-term extension | 1-3 years | $2,000 – $3,900+ | Continued access if treatment works | Significant time commitment |
The University of Wisconsin has offered up to $1,350 for asthma research participation, while Clinical Research of West Florida has provided up to $1,100. UVA Health compensates screening visits at up to $125. For longer studies spanning 22 months with 26 onsite visits, some sponsors have offered compensation reaching approximately $3,900. These figures are not wages—they are structured payments intended to offset time, travel, and inconvenience.
Investigational medications, study-related tests, and trial-specific procedures are covered by the sponsor. Participants do not receive a bill for these items. However, routine care that would happen regardless of the trial—like a standard asthma checkup—may still be billed to insurance. Clarifying this distinction with the study coordinator before enrolling is essential.
The American Lung Association's Airways Clinical Research Centers, one of the largest nonprofit trial networks in the country, typically provides compensation for time and travel for in-person visits. Their COPD-OMA study, which also touches on allergic asthma mechanisms, follows this model.
Finding a Trial That Fits
Searching for asthma clinical trials near me yields a flood of results, but not all listings are created equal. ClinicalTrials.gov remains the central registry, maintained by the National Library of Medicine. It is comprehensive but can feel impersonal. The American Lung Association curates a more accessible list of respiratory studies on its website, filtering for quality and relevance.
Several platforms have emerged to simplify the matching process. HelloStudys, for example, offers a two-minute prescreen for the Seabreeze STAT Asthma trial, letting potential participants check eligibility before committing to a phone call. Local research centers—AMR Clinical Research in Arizona, Avanza Medical Research Center in Florida, USF Health in Tampa—often maintain their own recruitment pages.
The inclusion and exclusion criteria can be narrow. A typical trial might require a confirmed asthma diagnosis, a specific range of lung function (FEV1), and a history of exacerbations. Some studies exclude patients with occupational asthma, other lung conditions like COPD or bronchiectasis, or recent use of immunosuppressive medications. Reading the eligibility section carefully saves time.
For parents considering pediatric asthma clinical trials, the process involves additional layers of consent. A parent or guardian must sign off, and the child's assent is usually required as well. Pediatric studies tend to have shorter visit windows, more flexible scheduling, and staff trained to work with younger participants.
Risks and Realities Worth Knowing
No trial is risk-free. Investigational treatments can cause side effects ranging from mild injection-site reactions to more serious events. The informed consent document outlines known risks based on preclinical data and earlier-phase studies, but unknown risks exist by definition. That is the nature of research.
There is also the possibility of receiving a placebo. For some patients, this is a dealbreaker. For others, it is acceptable because the standard-of-care medications continue, and the intensive monitoring often identifies issues that would have gone unnoticed in regular care. Patients in placebo groups sometimes report improved symptoms simply because they are more engaged with their health—a phenomenon researchers call the Hawthorne effect.
The time commitment should not be underestimated. A trial spanning 65 weeks, like the RENEW-Asthma study, requires sustained availability. Missed visits can compromise data and, in some cases, lead to withdrawal from the study. Patients with unpredictable work schedules or limited transportation should discuss these constraints with the coordinator before enrolling.
Regional Resources Across the Country
Different parts of the U.S. offer distinct research opportunities. Major academic medical centers in Boston, New York, and San Francisco run multiple concurrent asthma studies. But mid-sized cities are increasingly active. Tempe, Arizona and Westchester, Illinois have recruiting sites for the brenipatide trial. The Icahn School of Medicine at Mount Sinai in New York runs the SaMBA-WTC study for World Trade Center responders with asthma.
The American Lung Association's Airways Clinical Research Centers network spans the country, with hubs at Baylor College of Medicine in Houston, Columbia University in New York, and other institutions. These centers bridge the gap between academic research and community-based care, often running pragmatic trials that reflect real-world conditions more than tightly controlled lab settings.
For patients in rural areas, some trials offer telehealth components or mobile research units, though these are less common. The ClinicalTrials.gov search tool allows filtering by location and distance, making it possible to find studies within a manageable radius.
The landscape of asthma clinical trials in the United States in 2026 is wider and more patient-centered than many realize. Whether you are frustrated by symptoms that persist despite best efforts, curious about emerging therapies, or simply want to contribute to science that could help others breathe easier, the research infrastructure exists to connect you with a study. The first step is often the simplest: a conversation with your pulmonologist, a search on a trial registry, or a call to a local research center.
Michael, the construction supervisor from Phoenix, ultimately enrolled in a Phase 3 study after a two-week deliberation with his wife. He described the decision as "less about the money and more about finally trying something different." His symptoms have not vanished, but his lung function measurements have improved enough that his coordinator noticed before he did. He is not cured—asthma does not work that way—but he is breathing with a little less effort, and for now, that counts.
研究の知恵